RNAZ

TransCode Therapeutics, Inc.
CAPPED RATING

TransCode Therapeutics, Inc. (RNAZ) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D-). The rating has held at C- for 11 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
C-
Factor Score 2.0 / 5.0
Momentum
D-
Factor Score 0.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.2
EV / EBITDA -7.2
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -58.2%
Price Return 12M -85.0%
Catalyst Signal 0.00
Market Cap $22.3M
TTM Revenue N/A
Price / Sales N/A
ROE -59.3%

Historical Factor Score Progression

Held C- for 11 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C+ (2.5) C+ (2.5) C- (2.0) D- (0.7) C+ (2.6) C- (2.1)
2026-11-07 C+ (2.5) C+ (2.5) C- (2.0) F (0.6) C+ (2.7) C- (2.1)
2026-10-31 C+ (2.5) C+ (2.5) C- (2.0) F (0.6) C+ (2.7) C- (2.0)
2026-10-24 C+ (2.5) C+ (2.5) C- (2.0) F (0.5) C+ (2.6) C- (2.0)
2026-10-17 C+ (2.5) C+ (2.5) C- (2.0) F (0.4) C+ (2.6) C- (2.0)
Page 1 of 4